- Home
- CYRX vs MBX Comparison
CYRX vs MBX Comparison
Compare CYRX & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- MBX
- Stock Information
- Founded
- CYRX 1999
- MBX 2018
- Country
- CYRX United States
- MBX United States
- Employees
- CYRX N/A
- MBX N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- MBX
- Sector
- CYRX Health Care
- MBX
- Exchange
- CYRX Nasdaq
- MBX NYSE
- Market Cap
- CYRX 310.4M
- MBX 347.9M
- IPO Year
- CYRX N/A
- MBX 2024
- Fundamental
- Price
- CYRX $6.37
- MBX $7.38
- Analyst Decision
- CYRX Strong Buy
- MBX Strong Buy
- Analyst Count
- CYRX 6
- MBX 4
- Target Price
- CYRX $11.33
- MBX $37.25
- AVG Volume (30 Days)
- CYRX 649.7K
- MBX 218.2K
- Earning Date
- CYRX 03-04-2025
- MBX 03-17-2025
- Dividend Yield
- CYRX N/A
- MBX N/A
- EPS Growth
- CYRX N/A
- MBX N/A
- EPS
- CYRX N/A
- MBX N/A
- Revenue
- CYRX $228,385,000.00
- MBX N/A
- Revenue This Year
- CYRX $9.18
- MBX N/A
- Revenue Next Year
- CYRX $8.65
- MBX N/A
- P/E Ratio
- CYRX N/A
- MBX N/A
- Revenue Growth
- CYRX N/A
- MBX N/A
- 52 Week Low
- CYRX $4.58
- MBX $7.16
- 52 Week High
- CYRX $20.11
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- CYRX 54.54
- MBX N/A
- Support Level
- CYRX $5.90
- MBX N/A
- Resistance Level
- CYRX $6.60
- MBX N/A
- Average True Range (ATR)
- CYRX 0.61
- MBX 0.00
- MACD
- CYRX 0.09
- MBX 0.00
- Stochastic Oscillator
- CYRX 81.47
- MBX 0.00
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.